Mitochondrial DNA mutations and intercellular mitochondrial transfer in cancer: mechanisms, biological effects, and clinical potential
Chen Y., Shi H., Xiao M., Pan H., Yu X., Zhu Y.
Narrative Review, published in Biomark Res (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Biomark Res (2026)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41639740
- PMCID
- PMC12922255
- DOI
- 10.1186/s40364-026-00902-6
- Citations
- 1
Abstract (original English)
Mitochondrial DNA (mtDNA) mutations are frequently detected in tumor cells and represent a distinctive aspect of cancer genomics. Common types of mtDNA alterations include single nucleotide variants, insertions and deletions, and copy number changes. These mutations often result in a range of biological effects, encompassing both in situ and ectopic mechanisms. In situ, mutant mtDNA may lead to respiratory chain dysfunction, impairing oxidative phosphorylation and shifting energy production toward glycolysis and other metabolic pathways. This metabolic reprogramming, along with altered glutamine and lipid metabolism, is frequently accompanied by reactive oxygen species accumulation, which can activate pro-tumorigenic signaling cascades and contribute to genomic instability. These changes promote cancer cell proliferation, enhance invasive and metastatic potential, and facilitate immune evasion. Moreover, through mitochondrial transfer mechanisms such as tunneling nanotubes, extracellular vesicles, cell fusion, or gap junction channels, mutant mtDNA can be transmitted to other cells, serving as an important mode of intercellular communication within tumors. This process promotes tumor progression and metastasis, regulates apoptotic pathways, facilitates immune evasion, and enhances therapeutic resistance, allowing mutant mtDNA to exert ectopic effects. Clinically, mtDNA mutation
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.